Sahab Yaqubi, M.D.

Sahab Yaqubi
Post Doctoral Fellow, Genetics Program, BUSM

2004 M.D. National University of Iran, Tehran


My research interest focuses on the modulation of gene-environment interactions through DNA methylation in psychiatric disorders. I have been working on the role of epigenetic regulation of the Serotonin Receptor type-2(5HT2A) Promoter in Schizophrenia.

My further interest is in the genetic associated case-control study based on the finding in our clinical study. I have been working on a clinical study about the effect of Entacapone, a Cothecol-o-Methyl-Transferase (COMT) inhibitor drug, on substance dependency based on the hypothesis that the etiology of Reward (Dopamine) Deficiency Syndrome in substance abuse might be due to hyper activity of COMT leading to rapid Dopamine degradation in the synaptic cleft. This Dopamine deficiency could be more significant in specific part of Reward Pathway such as Ventral Tegmental Area, Nucleus Accumbance or Prefrontal cortex that may lead to addictive behaviors. Based on the preliminary results of ongoing studies, we have proposed a case-control genetic association study to investigate the role of Val158Met polymorphism of COMT gene on substance abstinence in individuals who take Entavapone. In fact, we are looking for treatment of substance dependency in patients based on their genetic and epigenetic profile providing individualized therapeutics in substance dependency.


Abdolmaleky HM, Yaqubi S, Papageorgis P, Lambert A.W, Ozturk S and Thiagalingam S. Epigenetic dysregulation of HTR2A in post-mortem Brain of patients with schizophrenia and bipolar disorder. Presented in BUSM in Evans Day2008. Manuscript in preparation.

Abdolmaleky HM, Yaqubi S and Thiagalingam S, “Promoter DNA hypo-methylation of the Serotonin Receptor-2 in Schizophrenia.”, Abstract presented in Boston University School of Medicine, Boston, MA . Oct 2008.

Shafa R, Abdolmaleky HM, Yaqubi S, Smith CL, Ghaemi SN. Entacapone as an Anti-Craving Treatment in Substance Abuse and Dependence. The American Journal on Addictions. 2008;17(4)331-332

Shafa R, Abdolmaleky HM, Yaqubi S, Smith CL, Koziol R, Ghaemi SN,” Entacapone(COMTAN)® in treatment of bipolar depression in patients with or without co-morbidity of substance abuse.” Poster presented at XXVΙ Collegiums International Neuro-psychopharmacologicum. July 2008, Munich, Germany.

Shafa R, Abdolmaleky HM, Yaqubi S, Smith CL, Tsuang M, Ghaemi SN, “A Successful Trial of Cathecol-O-Methyltransferase (COMT) Inhibitor Agent (Entacapone) in Treatment of Negative and Positive Symptoms of Schizophrenia. (A Pilot Study).” Poster presented at American Psychiatric Association May 2008, Washington DC.

Shafa R, Abdolmaleky HM, Yaqubi S, Ghaemi SN, “ Entacapone as a novel anti-craving treatment in Substance abuse and Dependence.” Poster presented at American Academy of Addiction Psychiatry November 2007, SanDiego, CA.

Shafa R, Abdolmaleky HM, Yaqubi S, Ghaemi SN, “Entacapone in Treatment of Schizophrenia, Bipolar Disorder and Substance Dependence.” Poster presented at World Congress of Psychiatric Genetics XV October 2007 NYC, NY.

December 15, 2009
Primary teaching affiliate
of BU School of Medicine